|1.||Bhatnagar, Aruni: 2 articles (04/2008 - 04/2006)|
|2.||Srivastava, Sanjay: 2 articles (04/2008 - 04/2006)|
|3.||Lavecchia, Antonio: 2 articles (01/2005 - 04/2003)|
|4.||Greco, Giovanni: 2 articles (01/2005 - 04/2003)|
|5.||Boldrini, Enrico: 2 articles (01/2005 - 04/2003)|
|6.||La Motta, Concettina: 2 articles (01/2005 - 04/2003)|
|7.||Novellino, Ettore: 2 articles (01/2005 - 04/2003)|
|8.||Da Settimo, Federico: 2 articles (01/2005 - 04/2003)|
|9.||Primofiore, Giampaolo: 2 articles (01/2005 - 04/2003)|
|10.||Cousido-Siah, Alexandra: 1 article (02/2013)|
|1.||Diabetic Neuropathies (Diabetic Neuropathy)
12/01/1995 - "In conclusion, one-year treatment with Tolrestat significantly improved oesophageal motility and vibration perception in Type-2 diabetic patients with asymptomatic diabetic neuropathy."
01/01/1992 - "As part of a larger European trial, we report here the results from a single clinical center on the efficacy of tolrestat in patients with confirmed diabetic neuropathy. "
10/01/1996 - "These results suggest that nerve regeneration is impaired in diabetic neuropathy and that tolrestat can prevent this impairment."
12/01/1995 - "The improvement after six months of therapy was mild but significant; therefore the authors conclude that the tolrestat is an useful drug in the treatment of the peripheral diabetic neuropathy in addition to attainment of a better glycemia's control."
12/01/1995 - "Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy."
|2.||Peripheral Nervous System Diseases (PNS Diseases)
01/01/1992 - "Tolrestat may therefore be helpful in diabetic peripheral neuropathy, where there is little opportunity for therapeutic intervention apart from effort to achieve normoglycaemic control."
10/01/1996 - "The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. "
10/01/1996 - "The aim of this meta-analysis was to review the existent evidence on the effectiveness of tolrestat in the treatment of diabetic peripheral neuropathy. "
12/01/1995 - "[Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?]."
01/01/1992 - "One hundred and ninety patients with symptomatic diabetic peripheral neuropathy took part in a double blind multicentre trial of either placebo or tolrestat 200 mg once daily for 6 months. "
07/01/1998 - "The effect of tolrestat (200 mg a day) was compared with that of placebo on 35 controls with diabetes mellitus, of similar age, gender, and glycemic control. "
12/01/1995 - "Tolrestat disposition was characterized by first-order absorption and biexponential disposition: In normal subjects the terminal disposition half-life (t1/2) was 13 +/- 3 hours (mean +/- SD) and the apparent oral clearance (CL/F) was 48 +/- 9 ml/hr/kg, similar to the values in patients with type I diabetes mellitus (t1/2 = 14 +/- 4 hours; CL/F = 55 +/- 10 ml/hr/kg). "
09/01/1993 - "We studied 100 elderly subjects affected by diabetes mellitus who were treated with tolrestat, an ARI, for a year and a control group who received a placebo. "
01/01/2002 - "In conclusion, our results suggest that aminoguanidine may be an important agent for the prevention of renal changes, whereas tolrestat may be effective for the prevention of ocular changes in diabetes mellitus."
01/01/1998 - "This prospective, randomised, double-blind, placebo-controlled study analysed the long-term effect of an aldose reductase inhibitor, tolrestat, on HRV time and frequency domain variables in 45 patients with diabetes mellitus (DM) and DAN. "
|4.||Carpal Tunnel Syndrome
12/01/1995 - "We conclude that treatment of this case series with Tolrestat appears to produce beneficial effect on the outcome of carpal tunnel syndrome in diabetic patients."
12/01/1995 - "The aim of this study was to test the efficacy of the aldose-reductase inhibitor Tolrestat in the treatment of carpal tunnel syndrome in Type 2 diabetic patients. "
01/17/2005 - "Moreover, compound 3 was found to be highly potent in preventing cataract development in severely galactosemic rats, like tolrestat, when administered as an eyedrop solution. "
04/10/2003 - "The isopropyl ester 59, a prodrug of 55, was found to be almost as effective as tolrestat in preventing cataract development in severely galactosemic rats when administered as an eye drop solution. "
04/01/1985 - "In view of the established similarity in the pathogenesis of galactosemic and diabetic cataracts, the results obtained with tolrestat support its potential for controlling cataract development in diabetics."
04/01/1985 - "In rats fed 30% galactose for 31 days, the controlling effect of tolrestat was dose dependent, and no cataracts were detected at a dose of 35 mg/kg/day. "
04/01/1985 - "Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, tolrestat."
|1.||Aldehyde Reductase (Aldose Reductase)